Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec Compensation
confidence 92%
filed 2026-06-26
Item 5.02
The Item 5.02 disclosure centers on two compensatory arrangements: (1) a new Executive Placement Agreement with SBR Limited for COO Jeroen Nieuwkoop providing $400,000 annual base salary, discretionary bonus up to 100% of base, and $1,000,000 annual equity awards plus $2,000,000 in initial RSU grants; and (2) a First Amendment to CEO David Schamis's employment agreement increasing his base salary to $600,000 and providing annual equity awards of $2,000,000–$3,000,000. These are material compensatory arrangements affecting named executives, not departures or appointments of new individuals.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-26
Item 5.02
James E. Davison, a board member of Genesis Energy's general partner, notified the Board of his retirement effective June 26, 2026. The disclosure centers on a director's departure from the board, which is a material governance event affecting the composition of the company's leadership. The explicit statement that the resignation was not due to disagreement further confirms this is a straightforward departure disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-26
Item 5.07
This Item 5.07 disclosure reports the final results of StubHub's annual stockholder meeting held on June 23, 2026, covering four proposals: election of seven directors, ratification of PricewaterhouseCoopers LLP as auditors, advisory approval of named executive officer compensation (say-on-pay), and advisory approval of say-on-pay voting frequency. The filing presents detailed vote tallies for each proposal, all of which passed. This is a classic shareholder_vote_results event as defined in Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-26
Item 5.02
The disclosure centers on a $4 million retention bonus agreement with Artem Yegorov, the Chief Technology Officer, contingent on his continued employment through the fourth anniversary of the effective date. This is a compensatory arrangement for a named executive officer, fitting the exec_compensation category. The materiality is clear given the size of the bonus and its strategic importance to retaining a key technology executive.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-26
Item 1.01
The filing discloses entry into a Fourth Amendment to an existing Credit Agreement with Wells Fargo, extending the maturity date from March 31, 2027 to March 31, 2028. While this is technically an amendment rather than a new debt issuance, it represents a material modification of a direct financial obligation that extends the company's access to credit facilities. The Item 1.01 classification and the language "entered into a Material Definitive Agreement" signal materiality, though the amendment preserves all other terms without modification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-26
Item 8.01
Viridian announced FDA approval and immediate commercial launch of Lumvoa™ (veligrotug-vvze) for thyroid eye disease treatment, marking the company's transition from development-stage to commercial operations with its first FDA-approved medicine.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 92%
filed 2026-06-26
The 6-K discloses a court decision in an unfair competition case brought by Turkish drivers' and automobile trade associations against Marti's ride-hailing subsidiary. The Istanbul 14th Commercial Court of First Instance partially granted plaintiffs' claims, finding the ride-hailing service constitutes unfair competition under Turkish Commercial Code, though it rejected requests for an injunction and claims regarding e-scooter and e-moped services. The Company intends to appeal to the Istanbul Regional Court of Appeals. This is a material litigation outcome affecting a core business line (ride-hailing) in the Company's primary market.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-06-26
Item 1.01
ENDRA Life Sciences Inc. entered into an Agreement and Plan of Merger on June 25, 2026, whereby its subsidiary will merge with and into Noble Africa LLC (a South African helium and LNG project company owned by Renergen Limited), with Noble surviving as a direct wholly-owned subsidiary of ENDRA. The transaction represents a transformative change of control involving approximately $50 million in equity financing, a dual-class share structure, and board composition changes, with ENDRA shareholders required to vote on the transaction and the company planning to file a Form S-4 registration statement.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-26
EX-99.1
The exhibit discloses the completion of a material disposition on June 17, 2026: the sale of all issued and outstanding shares of Ohmyhome (BVI) Limited, the company's wholly-owned subsidiary comprising its former property-related business, for $1 in cash. The document explicitly states this "Disposition represents a strategic shift in the Company's business focus to digital marketing services and qualifies for reporting as discontinued operations." The pro forma financial statements demonstrate the magnitude of the divested business—the disposed entity represented approximately $9.3 billion in historical revenues for 2025 and substantial assets and liabilities. This is a material change of control and disposition event requiring disclosure under Item 1.02 or 2.01 of Form 8-K equivalents.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-06-26
EX-99.1
This exhibit is a press release announcing Yiren Digital's unaudited financial results for the first quarter ended March 31, 2026. It discloses total net revenue of RMB915.1 million (down 41% year-over-year), a net loss of RMB494.7 million (compared to net income of RMB247.5 million in Q1 2025), and operational metrics across credit solutions and insurance brokerage segments. The document explicitly states "Yiren Digital Reports First Quarter 2026 Unaudited Financial Results" and includes detailed financial performance data, making it a discrete earnings announcement rather than a periodic financial report filing.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-06-26
EX-99.1
The Company completed a 1-for-16 share consolidation effective June 22, 2026, which was approved by shareholders on May 28, 2026 and the board on May 14, 2026. The consolidation was undertaken to maintain Nasdaq listing compliance and materially changes the share count and trading mechanics, including assignment of a new CUSIP.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-26
EX-99.2
The Company signed supply agreements to deliver AI-powered automotive painting robots and spray booth systems to customers in West and Southern Africa, with plans for East Africa expansion. This material business development represents a significant step in the Company's international expansion strategy and is expected to serve as a foundation for further market penetration.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-26
Item 4.01 discloses that CBIZ was dismissed effective June 26, 2026 and KPMG LLP was engaged as the Company's principal accountants, with the change approved by the Audit Committee. The filing explicitly states there were no disagreements with CBIZ on accounting principles, practices, or auditing scope, and CBIZ's audit report contained no adverse opinions or qualifications. This is a straightforward auditor change event material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-26
EX-99.1
The press release announces the allowance of a Japanese patent (JP 2025-049941) covering Namodenoson's use for fat loss and obesity treatment. This is a material intellectual property milestone that strengthens the company's global patent portfolio in a major pharmaceutical market and supports future partnering opportunities for a lead drug candidate in a rapidly expanding $60+ billion obesity therapeutics market. While not a discrete event type like M&A or exec change, it is a significant operational/strategic development affecting the company's competitive positioning and asset value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-26
EX-99.1
Maris-Tech announced award of a government defense contract valued at approximately $350,000 as prime contractor to develop and supply a MIL-STD vehicle-mounted audio system. The press release emphasizes this as "a significant milestone" and "an important strategic milestone" marking the company's first prime contractor role and expansion beyond its core edge video and AI portfolio into adjacent defense systems. This is a material operational/strategic event affecting the company's business trajectory and market positioning, though it does not fit the specific categories of M&A, earnings, executive changes, or other named event types.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-06-26
Item 3.02
Ondas Inc. conducted unregistered sales of equity securities to non-U.S. investors under Regulation S exemption, resulting in dilution to existing shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-26
Item 8.01
Ondas Inc. filed a prospectus supplement for resale registration of 3.4 million shares acquired as equity consideration in two material acquisitions: Omnisys Ltd. (3.3M shares, May 21, 2026) and World View Enterprises Inc. (92K shares, April 1, 2026).
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-26
EX-99.1
The press release announces the successful completion of a strategic transaction between SaverOne and VisionWave Holdings, with SaverOne receiving approximately $7 million in VisionWave common stock as total consideration. This represents a material acquisition or strategic investment activity that deepens the companies' collaboration in RF technology for defense and security markets. The transaction was first announced in January 2026 and completion of all stages is now disclosed, constituting a material M&A event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-26
Item 7.01
Columbus Circle Capital Corp II (CMII/IPAC) entered into a definitive Business Combination Agreement with Elroy Air, Inc. on June 26, 2026, whereby Merger Sub will merge with and into Elroy Air, with Elroy Air as the surviving company. The transaction values Elroy Air at $800 million pre-money with approximately $1.0 billion post-transaction enterprise value and $165+ million in committed PIPE capital. This is a material acquisition/change of control transaction expected to close in Q4 2026, subject to shareholder approval and customary closing conditions.
View raw filing on EDGAR →
6-K
Auditor Change
confidence 95%
filed 2026-06-26
The 6-K discloses the dismissal of Audit Alliance LLP effective June 22, 2026, and the engagement of Li CPA LLC as the new independent auditor on June 26, 2026. Both actions were approved by the Audit Committee and Board. The filing explicitly states there were no disagreements, adverse opinions, or reportable events, indicating a routine auditor transition. This is a classic auditor_change event under Item 4.01 of Form 20-F (the foreign-issuer equivalent).
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-26
EX-99.1
This press release announces a registered direct offering of 400,000 ADSs at $10.00 per ADS (representing a 10.7% premium to market) for gross proceeds of $4.0 million, plus warrants to purchase 300,000 additional ADSs. The offering is being made pursuant to an effective Form F-3 shelf registration statement. This is a classic dilutive equity issuance to a strategic institutional investor, material to shareholders as it increases share count and dilutes existing ownership.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-26
EX-99.1
This exhibit is a formal "Report of Voting Results" dated June 26, 2026, disclosing the results of Titan Mining Corporation's Annual General Meeting held on June 25, 2026. The report presents voting outcomes on three matters: (1) setting the number of directors at seven, (2) election of seven named directors (Richard W. Warke, Donald R. Taylor, John Boehner, Lenard Boggio, William Mulrow, George Pataki, and Rita Adiani), and (3) appointment of Ernst and Young, LLP as auditors. This is a classic shareholder_vote_results disclosure under Item 5.07 of the 8-K taxonomy (or its 6-K equivalent), and is material because director elections and auditor appointments are fundamental governance matters affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 98%
filed 2026-06-26
EX-99.1
This is a formal Report of Voting Results from Highlander Silver Corp.'s Annual General Meeting held June 25, 2026, disclosing shareholder votes on director elections and auditor appointment. The document explicitly states it is filed under Section 11.3 of National Instrument 51-102 and presents detailed voting tallies for all matters voted upon, which is the hallmark of a shareholder_vote_results disclosure. Director elections and auditor appointments are material governance matters affecting investor assessment of board composition and financial oversight.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-26
The filing discloses the resignation of Ms. Yu-Tien Chiu, Chief Marketing Officer of Wetour Robotics Limited, effective immediately on June 25, 2026, for personal reasons. This is a clear executive departure under Item 5.02 of Form 8-K (or the 6-K equivalent), as the principal disclosed action is a named officer leaving her role. The CMO position is material to investor assessment of the company's leadership and marketing strategy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-06-26
Item 8.01
The filing discloses a Nasdaq listing compliance violation under Rule 5250(c)(1) due to failure to timely file the Form 10-K and subsequently the Form 10-Q. Although the Company ultimately cured the deficiency by filing the Form 10-Q on June 17, 2026, and Nasdaq confirmed compliance on June 23, 2026, the disclosure of the non-compliance notice and the risk of delisting that preceded the cure is material to investors. The Company's initial failure to meet continued listing standards represents a delisting risk event, even though it was subsequently resolved.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-26
The filing discloses Meihua's entry into a new Software-as-a-Service (SaaS) business segment through its U.S. subsidiary, Meihua Future, launched in July 2025. The company provides detailed strategic plans for medical registration and healthcare SaaS systems across North America, Hong Kong, and Southeast Asia, with cumulative signed contracts of USD 16.125 million as of month-end. This represents a material strategic business pivot from the company's traditional medical device manufacturing operations, warranting classification as a significant operational/strategic initiative that would affect a reasonable investor's assessment of the registrant's business direction and growth prospects.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-06-26
EX-99.1
This is a press release announcing Helport AI's unaudited financial results for the six months ended December 31, 2025. The exhibit discloses revenue of $17.7 million (up 7.7% period-over-period), gross profit of $9.1 million, and a net loss of $1.7 million (compared to net income of $1.1 million in the prior period). The disclosure includes detailed financial review, management commentary, and forward-looking guidance, all hallmarks of an earnings release. Material to investors as it reports interim financial performance and a swing from profitability to loss.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-26
Item 1.01
Cero Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions for up to $1,413,600 (with $663,600 funded on June 23, 2026), bearing 10% interest and maturing May 28, 2027. The note is convertible into common stock, creating both a direct financial obligation and a dilutive equity component.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-06-26
EX-99.1
Universe Pharmaceuticals announced entry into a share purchase agreement to acquire 100% of Best Praise International Limited for US$10.75 million in stock consideration (4,376,552 Class A ordinary shares). This is a material acquisition of a company holding five pharmaceutical patents. The transaction has been approved by the board and is expected to close in Q3 2026, representing a significant expansion of the Company's intellectual property portfolio and strategic direction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-26
Item 1.01
The Company entered into a Note Conversion Agreement on June 25, 2026, converting $4.13 million in principal and accrued interest from NLabs (an affiliate of the CEO) into 41,329 shares of Series A-1 Preferred Stock convertible into 13.3 million shares of Common Stock, plus warrants to purchase an additional 13.3 million shares, representing a material capital restructuring.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing discloses the appointment of Joseph Samuels as a Class I director of Willow Lane Acquisition Corp. II effective June 22, 2026. The disclosure includes his background as founder and CEO of Islet Management and prior experience as a Partner at Och-Ziff Capital Management, along with standard representations regarding family relationships and related-party transactions. This is a clear executive appointment under Item 5.02.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-26
The 6-K discloses the results of an annual general meeting held on June 26, 2026, reporting voting outcomes for two resolutions: (1) re-election of five board members (Ron Sade, Alyazi Saeed Ahmad Alkhattal Almheri, Erez Simha, Tariq Salem Ebraheem Alsaman Alnuaimi, and Keren Maimon) with specific vote tallies, and (2) ratification of Reliant CPA PC as independent auditor. This is a direct disclosure of shareholder vote results, matching the `shareholder_vote_results` taxonomy type. Board composition and auditor ratification are material governance matters affecting investor assessment.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 85%
filed 2026-06-26
The 6-K discloses a court-approved settlement agreement resolving litigation brought by Esousa Group Holdings, LLC against VCI Global Limited. The Petitioner alleged breach of reporting and registration obligations under Securities Purchase Agreements, and the settlement requires the Company to issue substantial Settlement Securities (over 7.4 million ordinary shares and warrants combined). Although the Company denies liability, the settlement involves material consideration and court approval following a fairness hearing, making this a material litigation settlement disclosure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-26
The 6-K discloses that WISeSat.Space Holdings Corp. (a subsidiary of WISeKey) filed a Form F-4 registration statement on June 23, 2026 relating to a previously announced proposed business combination with Columbus Acquisition Corp (COLA), a SPAC. The Business Combination Agreement was executed November 9, 2025, and upon completion, WISeSat and CAC will become subsidiaries of Pubco, with the combined company expected to trade on Nasdaq under ticker "SAIQ". This is a material M&A transaction—a SPAC merger—that would substantially alter WISeKey's corporate structure and ownership.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-26
Item 4.01
The filing discloses the dismissal of Summit Group CPAs, P.C. as the independent registered public accounting firm effective June 25, 2026, and the concurrent appointment of Davidson & Company LLP as the new auditor. This is a classic auditor change under Item 4.01. The disclosure confirms no disagreements or reportable events preceded the dismissal, indicating a routine transition rather than a restatement or audit failure. Auditor changes are material to investors as they affect financial reporting oversight and credibility.
View raw filing on EDGAR →
6-K
Material Litigation
confidence 95%
filed 2026-06-26
The 6-K discloses a material class action lawsuit certified by the Tel Aviv District Court on May 5, 2026, with the claim filed on June 25, 2026. The litigation alleges improper conduct in a private placement approved in March 2021, including claims of significant discount pricing and defects in the approval process. This is a certified class action against the Company, its officers, directors, and controlling shareholder—a material litigation event that would affect a reasonable investor's assessment of legal and financial risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 72%
filed 2026-06-26
Item 1.02
The filing discloses termination of a securities purchase agreement for a $1,000,000 private placement of 666,667 units at $1.50 per unit. While the termination itself is the stated Item 1.02 event, the material substance is the failure of a planned dilutive equity issuance that would have raised significant capital. For a small-cap company like Firefly Neuroscience, the loss of this $1M financing is material to investor assessment of liquidity and capital structure, even though the agreement was terminated rather than completed.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-06-26
AIOS Tech entered into a share subscription agreement on June 26, 2026, under which Swift Prime Limited (owned by director and Co-CEO Guo Li) will subscribe for 5,000,000 Class B common shares at par value (US$0.0001 per share). Upon completion, Mr. Guo Li will beneficially own approximately 60.6% of outstanding shares and 99.4% of voting power. This is a material dilutive issuance of equity securities at a nominal price, resulting in a significant change of control and voting concentration that would materially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-26
Item 4.01
The filing discloses the dismissal of CBIZ CPAs as the Company's independent registered public accounting firm on June 24, 2026, and the concurrent appointment of Grassi & Co., CPAs, P.C. as the new auditor. This is a classic auditor change under Item 4.01. The disclosure is material because it involves a change in the registrant's certifying accountant and identifies material weaknesses in internal control over financial reporting, which would affect a reasonable investor's assessment of financial reporting quality and reliability.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-26
Item 1.01
The filing discloses entry into a securities purchase agreement for issuance of $50 million in aggregate principal amount of senior secured convertible notes bearing 15% interest, with an initial closing on November 5, 2025 and subsequent extension of the Initial Note maturity to August 31, 2026. This represents creation of a new direct financial obligation and is material to investors assessing the registrant's capital structure and debt burden.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-06-26
Item 2.02
Virtuix Holdings Inc. issued a press release on June 25, 2026 announcing financial and operational results for the fiscal year ended March 31, 2026, including net sales of $4.3 million (18% increase), gross profit of $1.0 million with 25% gross margin, operating expenses of $11.4 million, and cash position of $9.5 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-26
The filing discloses results of BiomX Inc.'s 2026 Annual Meeting of Stockholders held on June 26, 2026, including voting outcomes for three proposals: election of director Ran Shaked, approval of an amendment to the 2026 Equity Incentive Plan increasing shares reserved by 5,460,000, and approval of an adjournment proposal. This is a classic Item 5.07 shareholder vote results disclosure with certified voting tallies for each proposal.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-26
The filing discloses two material acquisition-related transactions: (1) a Securities Exchange Agreement with SecureKloud Technologies Ltd. involving the issuance of 2,828,167 common shares as a make-whole settlement for previously issued Series B Preferred Stock that became economically worthless due to reverse stock splits; and (2) Amendment No. 1 to a Share Purchase Agreement for the acquisition of companies through Teyame AI Holdings Inc., involving issuance of $12 million in restricted common stock, preferred stock convertible into 7.74 million shares, and earnout provisions. Both transactions involve material equity issuances and are disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), indicating significant capital structure changes and acquisition activity.
View raw filing on EDGAR →
8-K
Going Concern
confidence 95%
filed 2026-06-26
Item 8.01
The auditor's report explicitly states "substantial doubt about the Company's ability to continue as a going concern" because the Company "has limited cash available outside of its Trust Account and may not be able to access the funding necessary to consummate a business combination." This is a classic going-concern disclosure required by auditing standards and is material to investors evaluating a SPAC's viability.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-06-26
EX-99.1
TNL Mediagene received a Nasdaq staff determination letter on June 22, 2026, notifying the company that its securities are subject to delisting from The Nasdaq Capital Market due to two separate violations: (1) closing bid price below $1.00 per share for 30 consecutive business days, and (2) failure to meet the $2,500,000 minimum stockholders' equity requirement. The company is ineligible for a compliance period due to a prior reverse stock split. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially threatening the company's continued listing status.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-06-26
The filing discloses the dismissal of Reliant CPA PC as the Company's independent registered public accounting firm effective June 22, 2026, and the simultaneous appointment of Haskell & White LLP as the new auditor. While the prior auditor's reports contained a going-concern warning, the primary disclosed event is the auditor change itself under Item 4.01. This is material as auditor changes signal potential accounting or governance concerns and affect investor confidence in financial reporting.
View raw filing on EDGAR →
8-K
Going Concern
confidence 92%
filed 2026-06-26
Item 8.01
The auditor's report explicitly states that "substantial doubt about the Company's ability to continue as a going concern" exists due to expected significant expenses for identifying and evaluating business combination candidates without any operating revenues until after a business combination is completed. This is a classic going-concern disclosure required under auditing standards and is material to investors evaluating the registrant's viability.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-26
Item 5.02
HeartSciences Inc. entered into an Agreement and Plan of Merger on June 23, 2026, whereby the company will acquire Fortitude Mining Holdings, Inc. through a merger transaction.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-06-26
Item 3.02
HeartSciences issued unregistered equity securities as compensatory awards to officers or directors, with the disclosure incorporating Item 5.02 by reference and relying on officer/director representations regarding the exemption.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-26
Ms. Sim Peng Thia, a member of the Board of Directors, resigned effective June 23, 2026, due to personal reasons. The disclosure explicitly states her departure from the Board and all committees thereof. Board departures are material governance events that affect investor assessment of the registrant's leadership and control structure.
View raw filing on EDGAR →